Format

Send to

Choose Destination
Forsch Komplementmed. 2006 Feb;13 Suppl 1:23-7. Epub 2006 Feb 17.

[Efficacy and safety of Padma 28 in peripheral arterial occlusive disease].

[Article in German]

Author information

1
Institut für Naturheilkunde, Departement Innere Medizin, Universitätsspital Zürich, Schweiz. joerg.melzer@usz.ch

Abstract

BACKGROUND:

The multicompound herbal drug Padma 28 is based on a formula from Tibetan Medicine and has been used in Switzerland for over 30 years in the symptomatic treatment of circulatory disorders including intermittent claudication.

OBJECTIVE:

What is the current evidence regarding the clinical efficacy and safety of this drug in patients with peripheral arterial occlusive disease(PAOD)?

MATERIALS AND METHODS:

Electronic databases were searched (each from inception to fall 2005) as well as the reference lists of the relevant articles.

RESULTS:

14 articles were found including 6 published studies, 1 un-published study, 6 double publications and 1 meta-analysis. Six studies analyzed maximum walking distance, 5 of these showed a significant increase. The pooled data of the meta-analysis confirmed a significant and clinically relevant increase of the maximum walking distance by more than 100 m in about 1 out of 5 patients. Serious adverse events were not related to verum, non-serious adverse events were equally frequent as under placebo.

CONCLUSIONS:

The evidence available shows that the multi-target therapy with Padma 28 provides statistically significant and clinically relevant relief from PAOD-related symptoms, i.e. an increased walking distance.

PMID:
16582560
DOI:
10.1159/000091087
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center